Long COVID Trial, Recruiting NCT05894616 Sponsor: Karolinska Institutet Condition: Long COVID
Back to Long Covid

Long COVID Trial, Recruiting

NCT05894616
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the Long COVID group:

  • You had a confirmed COVID-19 infection (proven by a test or blood test before you were vaccinated) during the first or second wave of COVID-19 (before February 28, 2021)
  • Your COVID-19 symptoms have lasted more than 12 weeks after you first got sick
  • Your initial COVID-19 illness was mild to moderate and did not require a hospital stay
  • Your ongoing symptoms have at some point affected your ability to work by 50% or more
  • You have some lung-related problems, such as breathing difficulties, abnormal lung scan results, or airway issues (confirm with trial site for exact details)
  • You have experienced significant shortness of breath in the past 2 weeks, AND at least one of the following: reduced airflow in your lungs, reduced lung capacity, air getting trapped in your lungs, or specific abnormal findings on a detailed lung scan

For the Healthy Comparison group:

  • You had a confirmed COVID-19 infection during the first or second wave
  • You fully recovered within 12 weeks of first getting sick

Who may not be able to join:

  • You have a long-term (chronic) health condition of any kind, other than asthma
  • Note: If you were diagnosed with asthma after 2020, you may still be eligible for the Long COVID group (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Asa M. Wheelock, PhD, Karolinska Institutet

Phone: +46702200308

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 November 2022
Est. completion
31 December 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Home monitoring of health status using the eHealth tool HemCOV; Asthma evaluation using AsthmaTuner; Molecular characterization of particles in exhaled air (PExA); Molecular characterization of samples from the lung collected through bronchoscopy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov